Fresolimumab

DRUG5 trials

Conditions

Diffuse Systemic SclerosisMetastatic Breast CancerOsteogenesis ImperfectaPrimary Focal Segmental GlomerulosclerosisStage IA Non-Small Cell Lung CarcinomaStage IB Non-Small Cell Lung Carcinoma

Phase 1

Fresolimumab In Systemic Sclerosis

CompletedNCT01284322

Boston UniversityDiffuse Systemic Sclerosis

Start: 2011-01-31End: 2014-03-31Updated: 2014-07-16

SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer

CompletedNCT02581787

Maximilian DiehnStage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma

Start: 2016-08-31End: 2023-03-02Updated: 2024-03-27

Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta

CompletedNCT03064074

Baylor College of MedicineOsteogenesis Imperfecta

Start: 2017-11-15End: 2022-07-04Updated: 2024-12-04

Phase 2

Fresolimumab and Radiotherapy in Metastatic Breast Cancer

CompletedNCT01401062

Weill Medical College of Cornell UniversityMetastatic Breast Cancer

Start: 2011-07-31End: 2014-06-30Updated: 2019-03-05

A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)

CompletedNCT01665391

Genzyme, a Sanofi CompanyPrimary Focal Segmental Glomerulosclerosis

Start: 2012-08-31End: 2014-11-30Updated: 2015-08-26

Molecular Therapy — Oncolytics2023-12-0127 citations

MO211: Variability of Proteinuria in Nephrotic Syndrome: GC1008 PH2 Trial in FSGS

Nephrology Dialysis Transplantation2022-05-01

Targeting TGF-β for treatment of osteogenesis imperfecta

Journal of Clinical Investigation2022-02-0373 citations

Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients

Journal for ImmunoTherapy of Cancer2019-07-1153 citations

A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis.

2017-04-07113 citations

Abstract 4987: Role of the PD-1/PDL-1 pathway in resistance of patients with metastatic breast cancer to treatment with radiotherapy and TGFβ neutralization

Cancer Research2016-07-15

Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients

Journal of Clinical Investigation2015-06-21334 citations

Abstract 633: Inhibition of TGFβ as a strategy to convert the irradiated tumor into in situ individualized vaccine

Cancer Research2014-10-0117 citations

Fresolimumab

Sponsors

Conditions

Phase 1

Phase 2

Related Papers